Pair Name	Vitamin C, Anti-PD-1 antibody
Disease Info	[ICD-11: 2B33.5]	Lymphoma		Investigative
Biological Phenomena	Inhibition-->Anti-PD1 checkpoint
Gene Regulation	Up-regulation	Expression	GZMB	hsa3002
	Up-regulation	Expression	IL12B	hsa3593
In Vitro Model	A20	Reticulum cell sarcoma	Mus musculus (Mouse)	CVCL_1940
	SU-DHL-6	Diffuse large B-cell lymphoma germinal center B-cell type	Homo sapiens (Human)	CVCL_2206
	OCI-Ly1	Diffuse large B-cell lymphoma	Homo sapiens (Human)	CVCL_1879
	OCI-Ly7	Diffuse large B-cell lymphoma germinal center B-cell type	Homo sapiens (Human)	CVCL_1881
	OCI-Ly3	Diffuse large B-cell lymphoma activated B-cell type	Homo sapiens (Human)	CVCL_8800
In Vivo Model	40 BALB/c mice received a subcutaneous (s.c.) right flank injection of 5×10⁶ A20 tumor cells in phosphate-buffered saline (PBS) and were randomly assigned to 4 groups of 10 mice: vehicle, anti-PD1 (α-PD1), AA, and AA+α-PD1.
Result	This study shows that AA treatment 1) increases immunogenicity of lymphoma cells; 2) enhances intratumoral infiltration of CD8+ T cells and macrophages; and 3) synergizes with anti-PD1 checkpoint inhibition in a syngeneic lymphoma mouse model via marked activation of cytotoxic cells (cytotoxic T cells and NK cells) and antigen presenting cells. The data provide a compelling rationale for testing combinations of high-dose AA and anti-PD1 agents in patients with aggressive B cell lymphoma and in preclinical models of other malignancies.